Navigation Links
Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
Date:9/15/2008

Geneva, Switzerland 15th September, 2008: New research published today at the annual meeting of the American Society for Bone and Mineral Research (ASBMR), Montral, Canada, reveals that less than half (43%) of patients in Europe with osteoporosis are claiming to take both calcium and vitamin D supplementation with their osteoporosis treatment. Maximum benefit in managing osteoporosis can be achieved with combination therapy of an osteoporosis treatment (such as a bisphosphonate) with calcium and vitamin D supplementation, yet the majority of patients in this research claim they do not follow this approach.

"Patients with a low intake of calcium and vitamin D may not be receiving the full benefit of their osteoporosis treatment if they do not take enough supplementation", said Professor Steven Boonen MD, PhD, of Leuven University in Belgium and lead author of the abstract reporting the research results. "It is important that patients not only take both their calcium and vitamin D supplements, but also to ensure that they take them regularly".

The patient research was conducted amongst 383 women aged 50 years and older who had been diagnosed and treated for post-menopausal osteoporosis in France (n=97), Germany (n=98), Spain (n=94) and the UK (n=94). The aim of the study was to evaluate treatment knowledge and behaviour in women receiving treatment for their osteoporosis with regard to their calcium and vitamin D supplementation.

Patients need help to take supplementation regularly

Even when patients do take some form of supplementation, up to 30% claim they regularly miss a dose. An analysis of those patients who declared they were regularly missing a supplement dose revealed this was due either to the fact that they were not convinced of the importance of supplementation, or that they did not receive a detailed explanation from their treating physician. i Patient responses also showed that there is a need for some sort of aid, for example, a tool or packaging that would help them take their osteoporosis medication and supplementation. i This need for help is supported by patient preference data, which shows that over 70% of patients believe that providing a bisphosphonate with calcium and vitamin D in one box can help them take their supplements regularly and correctly.

Some European countries are performing better than others

The research highlights interesting differences in attitudes to supplementation across the four European countries. These study results showed that Spain generally proved to be a leader in terms of patient behaviour and knowledge about supplementation. For example, when looking at supplement use, 90% of patients in Spain claimed that they were taking some form of supplementation (calcium alone, vitamin D alone or calcium and vitamin D) with their osteoporosis treatment, compared to as few as 61% in the UK and 69% in France. i Similarly, patients in Spain claimed to discuss supplementation with their physician more regularly than in other countries - 51% compared to 36% in Germany, 24% in France and 9% in the UK.

Patient trends in the UK highlighted areas for improvement. As well as being the lowest users of supplements and one of the least likely to recognise the importance of calcium and vitamin D supplementation, almost a third of UK patients claimed to have never discussed supplementation with their physician. iv

When it came to adhering to supplements, women in France appeared to be the most disciplined out of the four countries, with only 13% claiming to regularly miss a dose of any supplement. This was in contrast to the UK, where almost one in three patients reported regularly missing a supplement dose. i

"The disparities between countries in attitudes to supplementation may be due to differences in cultures, national health policies or local disease awareness initiatives" said Doctor Patrice Fardellone, of CHU Amiens Hospital in France. "Whilst this research has shown some positive results, there is still room for improvement. It is vital that clinicians continue to educate their patients on the importance of supplements and encourage them to see supplementation as part of complete osteoporosis treatment."


'/>"/>

Contact: Nicki Barwise
nicola.barwise@ketchum.com
44-207-611-3885
Ketchum
Source:Eurekalert

Related biology news :

1. Majority of Americans want local action on global warming, says poll
2. ETH Zurich and IBM improve diagnosis of osteoporosis
3. USC School of Dentistry researchers uncover link between osteoporosis drugs and jaw infection
4. Early registrations to global osteoporosis conference
5. New research on structure of bones raises questions for treatment of osteoporosis
6. Hebrew SeniorLife researchers search for aging, osteoporosis genes
7. A home early warning system for cardiac patients
8. New sensory devices will aid Parkinsons and stroke patients
9. Unlocking mystery of why dopamine freezes Parkinsons patients
10. CMV infections affect more than just patients with compromised immune systems, researchers find
11. Smothered genes combine with mutations to yield poor outcome in cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
(Date:1/6/2016)... Jan. 6, 2016 Based on its ... & Sullivan recognizes MorphoTrak, LLC, a U.S. subsidiary ... Frost & Sullivan Company of the Year Award. ... technology, Morpho Wave™ , has consolidated the company,s ... biometrics market. Morpho Wave is a highly ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... Strasbourg, France , to the US ... Strasbourg, France , to the US company Advanced Bioscience ... announce that it acted as an advisor to Transgene on ... Strasbourg, France , to the US company Advanced Bioscience ... Transgene (Euronext: TNG), a member of Institut Mérieux, is ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology: